The risk of malignancy and its incidence in early rheumatoid arthritis patients treated with biologic DMARDs

BACKGROUND: Treatment with disease-modifying anti-rheumatic drugs (DMARDs) has raised concerns about the risk of malignancies in rheumatoid arthritis (RA) patients. However, the association between biologic DMARDs (bDMARDs) and malignancy in previous reports remains controversial. Therefore we aimed...

Descripción completa

Detalles Bibliográficos
Autores principales: Cho, Soo-Kyung, Lee, Jiyoung, Han, Minkyung, Bae, Sang-Cheol, Sung, Yoon-Kyoung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5732524/
https://www.ncbi.nlm.nih.gov/pubmed/29246243
http://dx.doi.org/10.1186/s13075-017-1482-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5732524/
https://www.ncbi.nlm.nih.gov/pubmed/29246243
http://dx.doi.org/10.1186/s13075-017-1482-y

Ejemplares similares